What is Citius Oncology, Inc.'s debt repayments?

Citius Oncology, Inc. (CTOR) reported debt repayments of $20M in Q3 2025.

What does debt repayments mean?

Cash used to repay or retire outstanding debt obligations, including scheduled maturities and early redemptions.

Merck & Co.MRK

$1.14B-54.4%

ImmunityBio, Inc.IBRX

$868K—

United TherapeuticsUTHR

$0-100%

Revenue$1.7M—

Gross profit$1.3M—

Operating income-$28.6M-283%

Net income-$26.6M-244%

EPS (diluted)-$0.27-145%

Cash & equivalents$2.6M+2,350,466%

Total equity$35.3M-1.0%

Total assets$100.7M+10.1%

Operating cash flow-$3.8M-179%

Market cap$60.45M-74.7%

Return on equity-119.9%+46.7pp

Current ratio0.5×+0.1×

Reported directly by Citius Oncology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RepaymentsOfNotesPayable.

The official record: Citius Oncology, Inc.’s 10-K, filed December 23, 2025, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Citius Oncology, Inc.'s debt repayments?: Citius Oncology, Inc. (CTOR) reported debt repayments of $20M in Q3 2025.
What does debt repayments mean?: Cash used to repay or retire outstanding debt obligations, including scheduled maturities and early redemptions.